Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy

J Neural Transm (Vienna). 2009 Feb;116(2):161-5. doi: 10.1007/s00702-008-0170-0. Epub 2008 Dec 17.

Abstract

Previous studies showed the reduction of dopamine transporter immunoreactivity (DAT-IR) in peripheral blood lymphocytes (PBL) in Parkinson's disease. Here we report the reduction of DAT-IR in PBL in the extrapyramidal variant of multiple system atrophy. These results suggest the reduction of DAT-IR in PBL in a variety of neurodegenerative disorders, provided the presence of damage of the central dopaminergic systems. The reduction of DAT-IR in PBL in these disorders may represent a compensatory phenomenon aimed at reducing intracellular dopamine influx and, consequently, dopamine-mediated aggravation of oxidative stress in these cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Dopamine Agents / therapeutic use
  • Dopamine Plasma Membrane Transport Proteins / biosynthesis*
  • Female
  • Humans
  • Immunohistochemistry
  • Levodopa / therapeutic use
  • Lymphocytes / metabolism*
  • Male
  • Middle Aged
  • Multiple System Atrophy / blood*
  • Multiple System Atrophy / drug therapy

Substances

  • Dopamine Agents
  • Dopamine Plasma Membrane Transport Proteins
  • Levodopa